Advertisement
Table 1 Baseline demographic and clinical characteristics stratified by 12 week and 24 week duration (n = 93)
| Characteristic, n (%) | Overall (n = 93) | 12 week (n = 61) | 24 week (n = 26) |
|---|---|---|---|
| Age, median (25%, 75%) | 41 (35–49) | 41 (34–49) | 40 (35–48) |
| Male sex, n (%) | 77 (83) | 49 (80) | 23 (88) |
| Drug use in the last 6 months (injecting/non-injecting) | 77 (83) | 48 (79) | 25 (96) |
| Injecting drug use in the last month | 55 (59) | 39 (64) | 15 (58) |
| Heroin | 33 (35) | 23 (37) | 10 (38) |
| Cocaine | 10 (11) | 7 (11) | 3 (12) |
| Amphetamines | 14 (15) | 7 (11) | 6 (23) |
| Other opiates | 11 (12) | 8 (13) | 3 (12) |
| Benzodiazapines | 2 (2) | 2 (3) | 0 (0) |
| Injecting drug use frequency in the last month | |||
| Never | 38 (41) | 22 (36) | 11 (42) |
| < daily | 40 (43) | 29 (48) | 10 (38) |
| > daily | 15 (16) | 10 (16) | 5 (19) |
| Opioid substitution treatment (ever) | 82 (88) | 56 (92) | 21 (81) |
| OST and recent injecting (past month) at enrolment | |||
| No OST, recent injecting | 30 (32) | 20 (33) | 9 (33) |
| OST, no recent injecting | 23 (25) | 15 (25) | 5 (19) |
| OST, recent injecting | 40 (43) | 26 (43) | 12 (44) |
| OST and recent injecting (past month) at baseline | |||
| No OST, recent injecting | 21 (23) | 14 (23) | 6 (23) |
| OST, no recent injecting | 34 (37) | 21 (34) | 8 (31) |
| OST, recent injecting | 38 (41) | 26 (43) | 12 (46) |
| Stage of liver disease | |||
| No or mild fibrosis (F0-F1) | 63 (68) | 44 (72) | 16 (62) |
| Moderate or advanced fibrosis (F2-F3) | 20 (22) | 12 (20) | 5 (19) |
| Cirrhosis (F4) | 10 (11) | 5 (8) | 5 (19) |
| Study site distribution | |||
| Europe | 38 (41) | 24 (39) | 13 (50) |
| Australia | 40 (43) | 27 (44) | 9 (35) |
| Canada | 15 (16) | 10 (16) | 4 (15) |
